Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2014 Jul 2

PMID 24983957

Citations 161

Authors

Matthias Eder

Oliver Neels

Miriam Muller

Ulrike Bauder-Wust

Yvonne Remde

Martin Schafer

Ute Hennrich

Michael Eisenhut

Ali Afshar-Oromieh

Uwe Haberkorn

Klaus Kopka

Affiliations

Soon will be listed here.

Abstract

The detection of prostate cancer lesions by PET imaging of the prostate-specific membrane antigen (PSMA) has gained highest clinical impact during the last years. 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) represents a successful novel PSMA inhibitor radiotracer which has recently demonstrated its suitability in individual first-in-man studies. The radiometal chelator HBED-CC used in this molecule represents a rather rarely used acyclic complexing agent with chemical characteristics favourably influencing the biological functionality of the PSMA inhibitor. The simple replacement of HBED-CC by the prominent radiometal chelator DOTA was shown to dramatically reduce the in vivo imaging quality of the respective 68Ga-labelled PSMA-targeted tracer proving that HBED-CC contributes intrinsically to the PSMA binding of the Glu-urea-Lys(Ahx) pharmacophore. Owing to the obvious growing clinical impact, this work aims to reflect the properties of HBED-CC as acyclic radiometal chelator and presents novel preclinical data and relevant aspects of the radiopharmaceutical production process of [68Ga]Ga-PSMA-HBED-CC.

Citing Articles

Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer.

Ismuha R, Ritawidya R, Daruwati I, Muchtaridi M Molecules. 2025; 29(24.

PMID: 39770150 PMC: 11679579. DOI: 10.3390/molecules29246062.

A comparison of routine [Ga]Ga-PSMA-11 preparation using Locametz and Illuccix kits.

Wang I, Morrissette L, Wong K, Brooks A, Dakanali M, Scott P EJNMMI Radiopharm Chem. 2024; 9(1):87.

PMID: 39692998 PMC: 11655735. DOI: 10.1186/s41181-024-00317-4.

Theranostics Nuclear Medicine in Prostate Cancer.

Lima H, Etchebehere M, Bogoni M, Torricelli C, Nogueira-Lima E, Deflon V Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598394 PMC: 11597825. DOI: 10.3390/ph17111483.

Inductively Coupled Plasma-Mass Spectrometry (ICP-MS): An Emerging Tool in Radiopharmaceutical Science.

Klika K, Han J, Busse M, Soloshonok V, Javahershenas R, Vanhaecke F J Am Chem Soc. 2024; 146(45):30717-30727.

PMID: 39478417 PMC: 11565647. DOI: 10.1021/jacs.4c12254.

Long-Term Tumor-Targeting Effect of as a Drug Delivery System.

Kim G, Lee H, Jeong D, Kim S, So J Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675383 PMC: 11053500. DOI: 10.3390/ph17040421.

References

Zhernosekov K, Filosofov D, Baum R, Aschoff P, Bihl H, Razbash A . Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007; 48(10):1741-8. DOI: 10.2967/jnumed.107.040378. View

Meyer G, Macke H, Schuhmacher J, Knapp W, Hofmann M . 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004; 31(8):1097-104. DOI: 10.1007/s00259-004-1486-0. View

Schultz M, Mueller D, Baum R, Watkins G, Breeman W . A new automated NaCl based robust method for routine production of gallium-68 labeled peptides. Appl Radiat Isot. 2012; 76:46-54. PMC: 5506834. DOI: 10.1016/j.apradiso.2012.08.011. View

Mu L, Hesselmann R, Oezdemir U, Bertschi L, Blanc A, Dragic M . Identification, characterization and suppression of side-products formed during the synthesis of high dose ⁶⁸Ga-DOTA-TATE. Appl Radiat Isot. 2012; 76:63-9. DOI: 10.1016/j.apradiso.2012.07.022. View

Eder M, Wangler B, Knackmuss S, LeGall F, Little M, Haberkorn U . Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies. Eur J Nucl Med Mol Imaging. 2008; 35(10):1878-86. DOI: 10.1007/s00259-008-0816-z. View

Eder M, Knackmuss S, Gall F, Reusch U, Rybin V, Little M . 68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur J Nucl Med Mol Imaging. 2010; 37(7):1397-407. DOI: 10.1007/s00259-010-1392-6. View

Schafer M, Bauder-Wust U, Leotta K, Zoller F, Mier W, Haberkorn U . A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012; 2(1):23. PMC: 3502552. DOI: 10.1186/2191-219X-2-23. View

Banerjee S, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox J . 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010; 53(14):5333-41. PMC: 3341619. DOI: 10.1021/jm100623e. View

Chen Y, Foss C, Byun Y, Nimmagadda S, Pullambhatla M, Fox J . Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008; 51(24):7933-43. PMC: 2631656. DOI: 10.1021/jm801055h. View

10.

Schuhmacher J, Klivenyi G, Matys R, Stadler M, Regiert T, Hauser H . Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res. 1995; 55(1):115-23. View

11.

Barrett J, Coleman R, Goldsmith S, Vallabhajosula S, Petry N, Cho S . First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013; 54(3):380-7. DOI: 10.2967/jnumed.112.111203. View

12.

Schuhmacher J, Klivenyi G, Hull W, Matys R, Hauser H, Kalthoff H . A bifunctional HBED-derivative for labeling of antibodies with 67Ga, 111In and 59Fe. Comparative biodistribution with 111In-DPTA and 131I-labeled antibodies in mice bearing antibody internalizing and non-internalizing tumors. Int J Rad Appl Instrum B. 1992; 19(8):809-24. DOI: 10.1016/0883-2897(92)90167-w. View

13.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

14.

Barinka C, Byun Y, Dusich C, Banerjee S, Chen Y, Castanares M . Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem. 2008; 51(24):7737-43. PMC: 5516903. DOI: 10.1021/jm800765e. View

15.

Banerjee S, Foss C, Castanares M, Mease R, Byun Y, Fox J . Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008; 51(15):4504-17. PMC: 3336105. DOI: 10.1021/jm800111u. View

16.

Cunha A, Weigle B, Kiessling A, Bachmann M, Rieber E . Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett. 2005; 236(2):229-38. DOI: 10.1016/j.canlet.2005.05.021. View

17.

Schulke N, Varlamova O, Donovan G, Ma D, Gardner J, Morrissey D . The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A. 2003; 100(22):12590-5. PMC: 240662. DOI: 10.1073/pnas.1735443100. View

18.

Fair W, Israeli R, Heston W . Prostate-specific membrane antigen. Prostate. 1997; 32(2):140-8. DOI: 10.1002/(sici)1097-0045(19970701)32:2<140::aid-pros9>3.0.co;2-q. View

19.

Eder M, Schafer M, Bauder-Wust U, Hull W, Wangler C, Mier W . 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23(4):688-97. DOI: 10.1021/bc200279b. View

20.

Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann C . [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012; 39(6):1085-6. DOI: 10.1007/s00259-012-2069-0. View